Stephanie Kacik

Current Trials

• An Open-Label, Multi-Centre Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T Cells in Patients With Advanced Non-Small Cell Lung Cancer

  HIC ID2000029536RoleSub InvestigatorPrimary Completion Date07/01/2023

  Recruiting Participants

  Lung Cancer

• A Multi-center Single Arm Phase II Study to Evaluate the Safety and Efficacy of Genetically Engineered Autologous Cells Expressing Anti-CD20 and Anti-CD19 Specific Chimeric Antigen Receptor in Subjects With Relapsed and/or Refractory Diffuse Large B Cell Lymphoma

  HIC ID2000028478RoleSub InvestigatorPrimary Completion Date07/30/2023

  Recruiting Participants

  Lymphoma

• A Phase 2, Single-arm, Multi-center Trial to Determine the Efficacy and Safety of JCAR017 in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma or With Other Aggressive B-Cell Malignancies

  HIC ID2000027145RoleSub InvestigatorPrimary Completion Date09/28/2028

  Recruiting Participants

  Lymphoma

• Managed Access Program (MAP) to Provide Access to CTL019, for ALL or DLBCL Patients With Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel Out of Specification for Commercial Release

  HIC ID2000025634RoleSub InvestigatorPrimary Completion Date07/06/2023

  Recruiting Participants

  LymphomaLeukemia